Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: Relevance for differential diagnosis

Tholander, Bengt; Taube, Adam; Lindgren, Anders; Sjöberg, Olof; Stendahl, U; A, Kiviranta; Hallman, Karin; Holm, Leif; Weiner, Erik; Tamsen, L.

doi:10.1016/0090-8258(90)90393-y

Cited by 38 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the flexibility of Lab-MAP technology allows for the addition of new markers and therefore for the opportunity to incrementally increase the diagnostic power of the combined assay. To the best of our knowledge, the reported multiplexed cytokines/CA-125 offers the highest predictive power, as compared with other published assays using defined protein serologic markers (3,14,30,(32)(33)(34)(35)(36)(37)(38)(39)(59)(60)(61)(62).…”

Section: Discussionmentioning

confidence: 85%

“…In some studies, combinations of several markers have been evaluated for early detection of ovarian cancer using conventional ELISA assays. Analysis of the diagnostic power of individual serologic markers in combination with CA-125 resulted in increased sensitivity and specificity (3,14,(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). Due to the limitations of ELISA (which is expensive, timeconsuming, and each assay encompasses only one marker at a time), none of the tested marker combinations thus far was sufficiently comprehensive and achieved the required characteristics for diagnosis of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Gorelik

Landsittel

Marrangoni

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

244

164

View full text Add to dashboard Cite

Early detection of ovarian cancer might improve clinical outcome. Some studies have shown the role of cytokines as a new group of tumor markers for ovarian cancer. We hypothesized that a panel comprised of multiple cytokines, which individually may not show strong correlation with the disease, might provide higher diagnostic power. To evaluate the diagnostic utility of cytokine panel, we used a novel multianalyte LabMAP profiling technology that allows simultaneous measurement of multiple markers. Concentrations of 24 cytokines (cytokines/chemokines, growth, and angiogenic factors) in combination with cancer antigen-125 (CA-125), were measured in sera of 44 patients with earlystage ovarian cancer, 45 healthy women, and 37 patients with benign pelvic tumors. Six markers, i.e., interleukin (IL)-6, IL-8, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), and CA-125, showed significant differences in serum concentrations between ovarian cancer and control groups. Out of this group, IL-6, IL-8, VEGF, EGF, and CA-125, were used in a classification tree analysis that resulted in 84% sensitivity at 95% specificity. The receiver operator characteristic curve created using the combination of markers produced sensitivities between 90% and 100% in the area of 80% to 90% specificity, whereas the receiver operator characteristic curve for CA-125 alone resulted in sensitivities of 70% to 80%. The classification tree analysis for discrimination of benign condition from ovarian cancer used CA-125, granulocyte colony-stimulating factor (G-CSF), IL-6, EGF, and VEGF resulting in 86.5% sensitivity and 93.0% specificity. The presented data show that simultaneous testing of a panel of serum cytokines and CA-125 using LabMAP technology may present a promising approach for ovarian cancer detection.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Gorelik

Landsittel

Marrangoni

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

244

164

View full text Add to dashboard Cite

show abstract

“…In contrast to its use in early detection, CA125 is more widely accepted as an adjunct in distinguishing benign from malignant disease in women, particularly in postmenopausal women presenting with ovarian masses (407,408,422 ), facilitating triage for operations by optimally qualified surgeons. Benign conditions resulting in increased CA125 levels may be a confounding factor in premenopausal women.…”

Section: Discrimination Of Pelvic Massesmentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

show abstract

“…The concentration of these Table 2 AntiKen values* (median, rmiges) in the studied subjects Groups n S.CEA ng/ml VF.CEA ng/ml S.CA125 U/ml VF.CA125 U/ml S.SCC ng/rnl VF.SCC nglml Study subjects 69 1.0 (0.5-8. 6) 186 ( CEA and SCC (18,26,27); whereas cervical mucus contains high quantities of CEA and CAI25 antigens ( 5 , 9). Therefore, both the endometrium and uterine cervix might also be the original, or additional sites of production of these antigens in the vaginal washout fluid.…”

Section: Discussionmentioning

confidence: 99%

“…Both biological fluid samples were immediately centrifuged to provide a cell-free fraction and kept at -20°C, until assay in the same run. Menopausal women (7) Third trimester (6) Fibromas (5) Cervicitis (7) Vaginitis ( Park, IL, 60064, USA). The sensitivities, intra-and interassay coefficients of variation (Cvs' Yo) for the kits were respectively: 0.5 ng/ml, 4.3, 5.2 for CEA; 3.0 U/ml, 3.2, 5.1 for CA125; and 0.3 ng/ml, 4.8, 6.5 for SCC.…”

Section: Methodsmentioning

confidence: 99%

Vaginal Fluid and Serum CEA, CA125 and SCC in Normal Conditions and in Benign and Malignant Diseases of the Genital Tract

et al. 1997

View full text Add to dashboard Cite

Carcinoembryonic antigen (CEA), CAI 25, and squamous cell carcinoma antigen (SCC) were evaluated in paired vaginal fluid and serum samples from 69 women, mean age 40.6 (20-78) years. Fifteen of the subjects were normal females (controls), 12 were pregnant, 20 had benign gynecological diseases. 5 presented severe cervical dysplasias and 17 suffered from cancer of the genital tract. Highly elevated CEA, CAI25 and SCC concentrations (median, range) were found in vaginal fluid: 186 ng/nil (12-5420); 890 U/ml (54-65000); 1600 ng/ml (27-13000) respectively, compared with those in the paired serum samples: I nglml (0.5S8.6): 12 U/ml (3.0-1 590): I ngiml (0.3-19). Vaginal fluid CEA. CAI25 and SCC values were significantly different among the five studied groups ( p <0.0002; p (0.02: p < 0.002 respectively). being significantly higher in the patients with benign gynecological diseases, compared with those in the patients with malignancies of the genital tract (p < 0,0001; p < 0.02; p < 0.005), and those in controls ( p < 0.02; p < 0.007: p < 0.02 respectively).The results of this study suggest that: 1) CEA. CAI25 and SCC seem to be normal constituents of vaginal fluid. 2) The distribution of CEA, CAI25 and SCC between vaginal fluid and the circulation is affected by pregnancy, inflammation and cancer of the genital tract.

show abstract

Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: Relevance for differential diagnosis

Cited by 38 publications

References 31 publications

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Vaginal Fluid and Serum CEA, CA125 and SCC in Normal Conditions and in Benign and Malignant Diseases of the Genital Tract

Contact Info

Product

Resources

About